The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with ...

The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510 ... Analysts think demand should drive blockbuster sales of $1 billion or more, particularly if the biopharma company ...

Sturm, Ruger & Company, Inc. is pleased to announce the appointment of Todd W. Seyfert as its next President and Chief Executive Officer, effective March 1, 2025. Mr. Seyfert brings to Ruger a ...

Most notably, RAMP-201 is a phase 2 study showed encouraging response ... defactinib in LGSOC continue to be the following: 1) Is avutometinib-defactinib acceptable efficacious in KRAS-wild ...

today announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small cell lung ...

In fact, the company recently reported data from their RAMP 203 Phase I/II study in KRAS G12C mutant advanced NSCLC for their triplet combination therapy comprising avutometinib and sotorasib plus ...

Currently, Amgen’s Lumakras (sotorasib) and Bristol-Myers Squibb ... D3S-002 and HER2×CD47 bispecific antibody D3L-000, in phase 1 development. The company has raised $250 million to date.